Brief: Mesoblast Says FDA Acknowledges Effects On Pain Intensity Favor Rexlemestrocel-L

Mesoblast

19/01/2026 24:04

Jan 18 (Reuters) - Mesoblast Ltd MSB.AX:

FDA ACKNOWLEDGES EFFECTS ON PAIN INTENSITY FAVOR REXLEMESTROCEL-L, CONFIRMS 12-MONTH REDUCTION IN BACK PAIN SUPPORTS PRODUCT EFFICACY

MESOBLAST LTD - SECOND PHASE 3 TRIAL MSB-DR004 OVER 50% ENROLLED

MESOBLAST LTD - SIGNIFICANT PAIN REDUCTION AND OPIOID CESSATION IN PHASE 3 TRIAL

MESOBLAST LTD - REXLEMESTROCEL-L RECEIVES RMAT DESIGNATION FROM FDA

Source text: ID:nGNX1Qh23k

Further company coverage: MSB.AX

 ((Reuters.Briefs@thomsonreuters.com;))